| 货号 | MAB273-500 |
| 描述 | For ELISA the Antibody Pairs information：Capture antibody：MAB273；Detection antibody：BAF273; and protein: 273-F9-025 |
| 别名 | FGF-9; fibroblast growth factor 9 (glia-activating factor); Fibroblast growth factor 9; GAF; glia-activating factor; HBFG-9; HBGF-9; Heparin-binding growth factor 9; MGC119914; MGC119915; SYNS3 | 全称 | Fibroblast Growth Factor 9 |
| 反应种属 | Human |
| 应用 | ELISA Capture (Matched Antibody Pair)(2-8 µg/mL ) ELISA Detection (Matched Antibody Pair)(0.1-0.4 µg/mL ) ELISA Standard ( ) |
| 目标/特异性 | Detects human FGF-9 in ELISAs. In sandwich immunoassays, no cross-reactivity or interference with recombinant human (rh) FGF-4, 5, 6, 7, 16, rhFGF acidic, or rhFGF basic is observed. |
| 使用方法 | ELISA Capture (Matched Antibody Pair): 2-8 µg/mL ELISA Detection (Matched Antibody Pair): 0.1-0.4 µg/mL ELISA Standard : Neutralization: Measured by its ability to neutralize FGF‑9-induced proliferation in the Balb/3T3 mouse embryonic fibroblast cell line. The Neutralization Dose (ND50) is typically 0.1-0.6 µg/mL in the presence of 10 ng/mL Recombinant Human FGF‑9. |
| 来源 | Monoclonal Mouse IgG2A Clone # 36912 |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 2254 (Human); 14180 (Mouse) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. FGF9 from cancer-associated fibroblasts is a possible mediator of invasion and anti-apoptosis of gastric cancer cells. | |
| 纯化方式 | Protein A or G purified from ascites |
| 免疫原 | S. frugiperda insect ovarian cell line Sf 21-derived recombinant human FGF-9 Met1-Ser208 Accession # P31371 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 背景 | The FGF family is comprised of at least nine polypeptides that show a variety of biological activities toward cells of mesenchymal, neuronal and epithelial origin. All FGFs have two conserved cysteine residues and share 30‑50% sequence identity at the amino acid level. FGF-9, also named glia-activating factor, was originally identified and purified from the supernatant of a human glioma cell line as a heparin-binding mitogenic growth factor for glial cells. FGF-9 has also been shown to stimulate the proliferation of oligodendrocyte type 2 astrocyte progenitor cells, Balb/c3T3 fibroblasts and PC-12 cells. However, unlike FGF acidic and basic, FGF-9 is not a mitogen for human umbilical vein endothelial cells. The human FGF-9 cDNA encodes a 208 amino acid residue protein that contains a potential N-linked glycosylation site. The native protein is glycosylated. FGF-9 exhibits approximately 30% sequence similarity to other members of the FGF family. Although FGF-9 lacks a typical secretion signal, the protein is secreted efficiently after synthesis. Rat FGF-9 cDNA has been cloned and shown to be highly homologous to human FGF-9. The two proteins differ only in one amino acid residue. The expression of the FGF-9 transcripts has been shown to be restricted to the brain and the kidney. |
| 运输条件 | Blue Ice |
| 存放说明 | -20℃ |
| 参考文献 |
|
Cell Proliferation Induced by FGF‑9 and Neutralization by Human FGF‑9 Antibody. Recombinant Human FGF‑9 (Catalog # 273-F9) stimulates proliferation in the Balb/3T3 mouse embryonic fibroblast cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human FGF‑9 (10 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human FGF‑9 Monoclonal Antibody (Catalog # MAB273). The ND50 is typically 0.1‑0.6 µg/mL. |
